- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07680959
Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia
The Efficacy of Combined HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia
Descripción general del estudio
Estado
Descripción detallada
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Taipei, Taiwán, 114
- Tri-Service General Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Subjects diagnosed with DSM-5 schizophrenia or schizoaffective disorder;
- With a clinical presentation characterized by predominant negative symptoms, as determined by psychiatric assessment and a score of at least 20 on the Negative Symptoms Subscale of the Positive and Negative Syndrome Scale (PANSS);
- Stable positive and negative symptoms for at least 4 weeks, as documented in medical records and confirmed by clinical judgment and psychiatric interview;
Exclusion Criteria:
- Unstable medical conditions;
- Current psychiatric comorbidity or active substance use disorder (except for tobacco use disorders);
- Contraindications for MRI, tDCS or rTMS;
- Pregnancy or breastfeeding at the time of enrollment;
- History of meningitis, encephalitis, seizures, intracranial neoplasms or surgery, severe head injury or cerebrovascular disease, or a family history of seizures;
- rTMS or tDCS treatment within the past 6 months as well as a history of electroconvulsive therapy (ECT);
- Any skin lesion at the stimulation sites;
- Patients receiving medications that significantly change the seizure threshold;
- A history of suicidal behavior within the past 6 months, or symptom worsening and emergence of suicidal ideation during the screening period.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: active iTBS followed by active HD-tDCS
During the 3-week intervention phase, patients in this group will receive 2 sessions of active iTBS per working day for 2 weeks (totaling 20 sessions), followed by 2 sessions of active HD-tDCS per working day for 1 week (totaling 10 sessions).
|
The active iTBS sessions will be delivered using the Magstim Rapid2 stimulator.
The iTBS protocol consists of 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) for 2 s at 8-s intervals for 60 cycles.
A 2-s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.
The intensity of stimulation will be set at 80% resting motor threshold (RMT).
The target will be the left DLPFC with the coil centered at the MNI coordinate [-38, 44, 26] calculated from T1-weighted MRI.
The active HD-tDCS will be applied by NeuroConn DC Stimulator Plus.
The central anode will be placed over the International 10-20 electrode position F3 and the return peripheral electrodes placed at Fp1, Fz, C3 and F7.
Stimulation session will be applied at an intensity of 2 mA, 8-sec fade in and 5-sec fade out, for 20 min.
During each session, the subject has to perform a computerized working memory task (i.e., 2-back task).
The two times daily sessions will be separated by at least 2 hours.
|
|
Experimental: sham iTBS followed by active HD-tDCS
During the 3-week intervention phase, patients in this group will receive 2 sessions of sham iTBS per working day for 2 weeks (totaling 20 sessions), followed by 2 sessions of active HD-tDCS per working day for 1 week (totaling 10 sessions).
|
In the sham iTBS condition, the patients receive the same iTBS regimen and exact positioning of the coil but stimulations will be delivered using a commercial identical looking figure 8 sham coil (Magstim D70 Air film sham coil) that can produce a similar sound and sensation.
In the active HD-tDCS condition, stimulation will be applied by a battery-operated device (NeuroConn DC Stimulator Plus) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration).
To target the left DLPFC, the central electrode (anode) will be placed over International 10-20 electrode position F3, with return peripheral electrodes at Fp1, Fz, C3 and F7.
Stimulation will be applied at an intensity of 2 milliamp (mA), 8-sec fade in and 5-sec fade out, for 20 min.
During each session, the subject has to perform a computerized working memory task (i.e., 2-back task).
The two times daily sessions will be separated by at least 2 hours.
|
|
Experimental: active iTBS followed by sham HD-tDCS
During the 3-week intervention phase, patients in this group will receive 2 sessions of active iTBS per working day for 2 weeks (totaling 20 sessions), followed by 2 sessions of sham HD-tDCS per working day for 1 week (totaling 10 sessions).
|
The active iTBS sessions will be delivered using the Magstim Rapid2 stimulator.
The iTBS protocol consists of 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) for 2 s at 8-s intervals for 60 cycles.
A 2-s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.
The intensity of stimulation will be set at 80% resting motor threshold (RMT).
The target is the left DLPFC with the coil centered at the MNI coordinate [-38, 44, 26] calculated from T1-weighted MRI.
In the sham HD-tDCS stimulation, short continuous currents without neuromodulatory effects will be applied to mimic real-stimulation sensations.
Specifically, sham stimulation will deliver 40-sec, 2 mA normal-like stimulation, followed by a tiny current pulse (110 μA over 15 ms) for impedance control taking place every 550 ms for the remaining time.
The other procedure is the same as the active HD-tDCS stimulation.
|
|
Comparador falso: sham iTBS followed by sham HD-tDCS
During the 3-week intervention phase, patients in this group will receive 2 sessions of sham iTBS per working day for 2 weeks (totaling 20 sessions), followed by 2 sessions of sham HD-tDCS per working day for 1 week (totaling 10 sessions).
|
In the sham iTBS condition, patients receive the same iTBS regimen and exact positioning of the coil but stimulations will be delivered using a commercial identical looking figure 8 sham coil (Magstim D70 Air film sham coil) that can produce a similar sound and sensation.
In the sham HD-tDCS condition, short continuous currents without neuromodulatory effects will be applied to mimic real-stimulation sensations.
Specifically, sham stimulation will deliver 40-sec, 2 mA normal-like stimulation, followed by a tiny current pulse (110 μA over 15 ms) for impedance control taking place every 550 ms for the remaining time.
The other procedure is the same as the active HD-tDCS stimulation.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The change in Positive and Negative Syndrome Scale (PANSS) negative subscale score
Periodo de tiempo: Fifteen weeks
|
PANSS is a clinician-administered rating scale to measure the severity of psychopathological symptoms of the patients with schizophrenia spectrum disorder. The patient is rated from 1 to 7 on 30 different symptom items. All items scores are summed up to yield a total PANSS score, which ranges from 30 to 210. A higher score indicates greater psychopathological symptom severity. PANSS negative subscale has 7 items with its score ranging from 7 to 49. The changes in the PANSS negative subscale score immediately after the 3-week intervention (primary endpoint), as well as at one-month and three-month follow-ups, will be collected as the primary outcome. |
Fifteen weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The change in score of the Scale for the Assessment of Negative Symptoms (SANS)
Periodo de tiempo: Fifteen weeks
|
The Scale for the Assessment of Negative Symptoms (SANS) is used to assess negative symptoms in schizophrenia on a 25 item, 6-point scale.
The SANS measures five domains of the negative symptoms including affective flattening or blunting, alogia, avolition - apathy, anhedonia - Asociality, Attention.
In each domain, separate symptoms are rated from 0 (absent) to 5 (severe).
A total SANS score ranges from 0 to 125.
The changes in the SANS score immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome.
|
Fifteen weeks
|
|
The change in score of Calgary Depression Rating Scale for Schizophrenia (CDSS)
Periodo de tiempo: Fifteen weeks
|
The participants' depressive symptoms will be measured by Calgary Depression Rating Scale for Schizophrenia (CDSS).
The changes in the CDSS score immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome.
|
Fifteen weeks
|
|
The change in the Personal and Social Performance scale (PSP) score
Periodo de tiempo: Fifteen weeks
|
PSP is a clinician-administered rating scale for measuring the psychosocial functioning of the patients with schizophrenia spectrum disorder. The PSP scale measures psychosocial functioning within four domains: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior.The patient is rated from 1 to 6 on each item of the four domains. A higher score indicates greater psychosocial functioning in any of the four domains. The final global score is defined according to a summary instruction table. This scale provides a single, overall rating from 1 to 100, where a higher score represents better personal and social function. The changes in the Personal and Social Performance scale (PSP) score immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome. |
Fifteen weeks
|
|
The change in the score of the Beck Cognitive Insight Scale (BCIS)
Periodo de tiempo: Fifteen weeks
|
Cognitive insight was measured by the Taiwanese version of the Beck Cognitive Insight Scale (BCIS), a self-reported instrument comprising 15 items.The Taiwanese BCIS is composed of 2 subscales including reflective attitude (9 items) and certain attitude (6 items).
We obtained a R-C (reflective attitude minus certain attitude) index of the Taiwanese BCIS, representing the measurement of cognitive insight by subtracting the score of the certain attitude subscale from that of the reflective attitude subscale.
Lower R-C index scores indicate poorer cognitive insight.
The changes in the score of the Beck Cognitive Insight Scale (BCIS) immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome.
|
Fifteen weeks
|
|
The change in the score of Schizophrenia Quality of Life Scale Revision Four (SQOLR4)
Periodo de tiempo: Fifteen weeks
|
The Chinese version of the Schizophrenia Quality of Life Scale Revision Four (SQOLR4) is a self-administered questionnaire of 33 items in two domains: psychosocial and vitality. All but four items are coded on a scale of 0-4 according to the frequency of occurrence during the previous 7 days (0 = always, 4 = never; the four exceptions are coded 0 = never, 4 = always). A higher score indicates higher health-related QoL. The changes in the score of Schizophrenia Quality of Life Scale Revision Four (SQOLR4) immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome. |
Fifteen weeks
|
|
The changes in the results of the Tower of London Drexel University Test 2nd Edition
Periodo de tiempo: Three weeks
|
The Tower of London Drexel University Test 2nd Edition is a neuropsychological test for the assessment of executive functioning specifically to detect deficits in planning, which may occur due to a variety of medical and neuropsychiatric conditions.
The changes in the results of the Tower of London Drexel University Test 2nd Edition immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in the results of the Color Trails Test (CTT)
Periodo de tiempo: Three weeks
|
The CTT, a culture-neutral version of the Trail Making Test, was selected to measure sustained visual attention.
The CTT consists of two parts (CTT-1 and CTT-2).
The CTT-1 requires participants to connect a series of numbered circles that are randomly printed on a sheet of paper.
In the CTT-2, numbered circles of 1 to 25 are shown twice (printed in pink and in yellow) randomly on a sheet of paper.
Participants are asked to connect the numbers from 1 to 25 alternating between the two colors.
The changes in the results of the Color Trails Test (CTT) immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in the results of the Stroop Color Word Test (SCWT)
Periodo de tiempo: Three weeks
|
Stroop Color Word Test (SCWT) will be administered to measure selective attention and cognitive flexibility.
SCWT is composed of three parts, each lasting for 45 seconds.
The changes in the results of the Stroop Color Word Test (SCWT) immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in fNIRS features
Periodo de tiempo: Three weeks
|
Functional near infrared spectroscopy (fNIRS) system is used to measure the relative changes in oxyhemoglobin (Hb) of the frontal regions.
Resting-state fNIRS fo 180s and verbal fluency task (VFT)-based fNIRS for 160s will be collected in a quiet room.
The changes in fNIRS features immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in resting-state fMRI features
Periodo de tiempo: Three weeks
|
Magnetic Resonance Imaging (MRI) scans will be performed on the hybrid 3.0T PET-MR imaging unit (GE Healthcare, Waukesha, WI).
MRI scans will be carried out using the same imaging protocol, including T1-weighted images and resting-state functional MRI (rs-fMRIs).The changes in resting-state fMRI features immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in indices of heart rate variability (HRV) derived from R-R intervals of ECG signals
Periodo de tiempo: Three weeks
|
HRV indices represent autonomic functioning. ECG electrodes will be placed on bilateral arms just below the elbows, with a ground electrode placed just above the right wrist bone. Lead I electrocardiogram of each patient will be taken for 5 min after sitting and having a rest for 20 min in a soundproof, dim-lighted room with thermostatic control. The ECG signals will be acquired, stored, pre-processed according to the recommended procedures and processed by an HRV analyser. The time domain of HRV is obtained: Standard deviation of NN intervals (SDNN). Power spectrum of HRV is quantified into the standard frequency-domain measurements including low-frequency power (LF, 0.04-0.15 Hz), high-frequency power (HF, 0.15- 0.40 Hz). The changes in indices of heart rate variability (HRV) derived from R-R intervals of ECG signals immediately after the 3-week intervention will be collected as the secondary outcome. |
Three weeks
|
|
The changes in resting-state EEG features
Periodo de tiempo: Three weeks
|
In a dimly lit, electrically shielded room, patients' electroencephalogram (EEG) will be recorded.
Resting-state EEG will be collected with eye opened (5min) and closed (5min).
Signals will be amplified by using EEG amplifiers and stored for offline analyses.
The changes in resting-state EEG features (power, coherence, and microstates within different frequency bands including delta, theta, alpha and beta) immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Hsin-An Chang, M.D., Tri-Service General Hospital (TSGH)
Publicaciones y enlaces útiles
Publicaciones Generales
- Kishi T, Ikuta T, Sakuma K, Hamanaka S, Nishii Y, Hatano M, Kito S, Iwata N. Theta Burst Stimulation Protocols for Schizophrenia: A Systematic Review and Network Meta-Analysis. JAMA Netw Open. 2024 Oct 1;7(10):e2441159. doi: 10.1001/jamanetworkopen.2024.41159.
- Tong S, Chen S, Chen J, Tong Z, Li W, Liu S, Shi H, Yao L, Zhang C, Zhang X. Efficacy and long-term effects of intermittent theta burst stimulation on negative symptoms in schizophrenia: a systematic review and meta-analysis. Brain Commun. 2026 Jan 29;8(1):fcag027. doi: 10.1093/braincomms/fcag027. eCollection 2026.
- Gupta R, Sharma A, Goyal N. Breaking the Negative Symptom Barrier: A Novel Neuromodulation Strategy Using HD-tDCS Primed iTBS in Schizophrenia. J ECT. 2026 Jan 20. doi: 10.1097/YCT.0000000000001224. Online ahead of print.
- Ma CC, Lin YY, Chung YA, Park SY, Huang CC, Chang WC, Chang HA. The two-back task leads to activity in the left dorsolateral prefrontal cortex in schizophrenia patients with predominant negative symptoms: a fNIRS study and its implication for tDCS. Exp Brain Res. 2024 Mar;242(3):585-597. doi: 10.1007/s00221-023-06769-5. Epub 2024 Jan 16.
- Yeh TC, Lin YY, Tzeng NS, Kao YC, Chung YA, Chang CC, Fang HW, Chang HA. Effects of online high-definition transcranial direct current stimulation over left dorsolateral prefrontal cortex on predominant negative symptoms and EEG functional connectivity in patients with schizophrenia: a randomized, double-blind, controlled trial. Psychiatry Clin Neurosci. 2025 Jan;79(1):2-11. doi: 10.1111/pcn.13745. Epub 2024 Sep 24.
- Lin CE, Chen LF, Sack AT, Chang HA. Task-based fNIRS biomarkers of HD-tDCS treatment for negative symptoms in schizophrenia. Schizophr Res. 2026 Aug;294:35-43. doi: 10.1016/j.schres.2026.04.010. Epub 2026 Apr 17.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- B202303001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .